J.P. Morgan Notebook Day 4: Kite, Cellectis and MannKind
This article was originally published in Scrip
Executive Summary
Kite Pharma Inc. presented the latest data from a trial of KTE-C19 in non-Hodgkin lymphoma as further evidence of strong efficacy for the chimeric antigen receptor T-cell (CAR-T) therapy. But the new data, which reflect product manufactured with Kite's new process, show higher rates of some side effects.
You may also be interested in...
Kite Pharma Details CAR-T Therapy Launch, Floats Pricing Benchmarks
Kite plans to initially target 72 clinical institutions experienced with CAR-T for its KTE-C19 launch, including 10 from the get-go.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.